| ID | 10010 |
| Vaccine Name | BBIBP-CorV (Vero cell) (Covilo) |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Live-attenuated |
| Vaccine Status | Approved |
| Manufacturer | China National Biotec Group Company Limited |
| Year of Manufacturing | 2021 |
| Manufacturing Country | China |
| Age | 18 years and above |
| Dosage | 2 doses 14 or 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | Aluminum |
| Target Strain | NA |
| Description | NA |
| Approving Organisation | WHO |
| Collaborating Organisation | Beijing Institute of Biotechnology |
| Other Countries | UAE, Jordan, Egypt, Bahrain, Argentina |
| Trade Name | BBIBP-CorV, COVILO |
| PMID | 32328406 |
| Clinical Trial ID | NA |
| Reference Link | https://pubmed.ncbi.nlm.nih.gov/32328406/ |
| Additional Links | https://www.precisionvaccinations.com/vaccines/sinopharm-covid-19-vaccine-bbibp-corv
|